Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.39 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 2/20 | 0.32 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 2/20 | 0.32 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.30 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL21715060 | 0.97 | TAAR1 (0.38) | TAAR1DGAT1KDM1AKDM1BHTR2A | |
| SCHEMBL29303353 | 0.84 | HTR1D (0.35) | TAAR1KDM1AKDM1B | |
| SCHEMBL20659323 | 0.84 | TAAR1 (0.34) | TAAR1KDM1AKDM1B | |
| SCHEMBL3980087 | 0.82 | TAAR1 (0.60) | TAAR1DGAT1HTR2AGPR17 | |
| SCHEMBL29303370 | 0.81 | KDM1A (0.34) | TAAR1KDM1AHTR2A | |
| SCHEMBL20879914 | 0.80 | TAAR1 (0.32) | TAAR1 | |
| SCHEMBL29303373 | 0.80 | CD274 (0.47) | TAAR1HTR2A | |
| SCHEMBL29303390 | 0.80 | AOC1 (0.33) | TAAR1 | |
| SCHEMBL29303383 | 0.78 | KDM1A (0.35) | KDM1AKDM1B | |
| SCHEMBL857045 | 0.78 | TAAR1 (0.42) | TAAR1HTR2AIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260138978-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1 | VANDERBILT UNIV (US) | 2026-05-21 | — | — | US | disclosed |
| EP-4729519-A1 | CRYSTAL FORM OF ENPP1 INHIBITOR | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) | 2026-04-22 | — | — | EP | disclosed |
| EP-4034094-B1 | PHOSPHODIESTERASE INHIBITORS AND USE | ZENSHINE PHARMACEUTICALS NANJING GROUP CO LTD (CN) | 2026-04-15 | — | — | EP | disclosed |
| US-20250206763-A1 | ENPP1 INHIBITOR | SHANGHAI QILU PHARMACEUTICAL RESEARCH AND DEVELOPMENT CENTRE LTD. (CN) | 2025-06-26 | — | — | US | disclosed |
| CN-115151253-B | Phosphodiesterase inhibitors and uses | 南京征祥医药有限公司 | 2025-04-15 | — | — | CN | disclosed |
| US-20250115609-A1 | AROMATIC HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR AND USES THEREOF | INNOVSTONE THERAPEUTICS LIMITED (CN) | 2025-04-10 | — | — | US | disclosed |
| CN-119497716-A | Crystal form of ENPP1 inhibitor | 石药集团中奇制药技术（石家庄）有限公司 | 2025-02-21 | — | — | CN | disclosed |
| WO-2024255837-A1 | CRYSTAL FORM OF ENPP1 INHIBITOR | 石药集团中奇制药技术（石家庄）有限公司 | 2024-12-19 | — | — | WO | disclosed |
| EP-4450503-A1 | AROMATIC HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR AND USES THEREOF | Innovstone Therapeutics Limited (CN) | 2024-10-23 | — | — | EP | disclosed |
| CN-118488950-A | ENPP1 inhibitors | 上海齐鲁制药研究中心有限公司 | 2024-08-13 | — | — | CN | disclosed |
| US-20140275029-A1 | 1,2,6-SUBSTITUTED BENZIMIDAZOLES AS FLAP MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-18 | — | — | US | disclosed |
| US-8563714-B2 | Bridged spiro [2.4] heptane derivatives as ALX receptor and/or FPRL2 agonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-10-22 | — | — | US | disclosed |
| EP-2432760-B1 | BRIDGED SPIRO [2.4] HEPTANE DERIVATIVES AS ALX RECEPTOR AND/OR FPRL2 AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2013-07-17 | — | — | EP | disclosed |
| US-8314250-B2 | Sultam derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-11-20 | — | — | US | disclosed |
| EP-2504324-A1 | SULTAM DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2012-10-03 | — | — | EP | disclosed |
| US-20120115841-A1 | BRIDGED SPIRO [2.4] HEPTANE DERIVATIVES AS ALX RECEPTOR AND/OR FPRL2 AGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-05-10 | — | — | US | disclosed |
| EP-2432760-A1 | BRIDGED SPIRO [2.4]HEPTANE DERIVATIVES AS ALX RECEPTOR AND/OR FPRL2 AGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2012-03-28 | — | — | EP | disclosed |
| WO-2011064141-A1 | SULTAM DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-03 | — | — | WO | disclosed |
| US-20110124686-A1 | SULTAM DERIVATIVES | ANDERSON KEVIN W | 2011-05-26 | — | — | US | disclosed |
| WO-2010134014-A1 | BRIDGED SPIRO [2.4] HEPTANE DERIVATIVES AS ALX RECEPTOR AND/OR FPRL2 AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2010-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115841-A1 | BRIDGED SPIRO [2.4] HEPTANE DERIVATIVES AS ALX RECEPTOR AND/OR FPRL2 AGONISTS | FPR1, FPR2, FPR3 | TAAR1 257/4885DGAT1 2050/4885KDM1A 4126/4885 |
| US-20140275029-A1 | 1,2,6-SUBSTITUTED BENZIMIDAZOLES AS FLAP MODULATORS | FEN1, FOXM1, F12 | TAAR1 3729/4885DGAT1 3978/4885KDM1A 356/4885 |
| US-20260138978-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1 | CHRM1, CHRM4, CHRM2 | TAAR1 60/4885DGAT1 1142/4885KDM1A 1149/4885 |
| US-20250206763-A1 | ENPP1 INHIBITOR | ENPP1, PPP1R1B, ENPP3 | TAAR1 4531/4885DGAT1 720/4885KDM1A 3536/4885 |
| US-20250115609-A1 | AROMATIC HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR AND USES THEREOF | ENPP1, WEE1, ENPP2 | TAAR1 4497/4885DGAT1 1315/4885KDM1A 2602/4885 |
| US-20110124686-A1 | SULTAM DERIVATIVES | SULT1A1, SULT2A1, SULT1E1 | TAAR1 2713/4885DGAT1 1037/4885KDM1A 1432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.